Literature DB >> 6781810

Mechanism of valproate-phenobarbital interaction in epileptic patients.

I M Kapetanović, H J Kupferberg, R J Porter, W Theodore, E Schulman, J K Penry.   

Abstract

Valproate effects on phenobarbital biodisposition were examined in a search for the mechanisms of the valproate-induced elevation of plasma phenobarbital during antiepileptic therapy. The study involved patients who were treated with phenobarbital alone and phenobarbital plus valproate. Several kinetic parameters were determined after a pulse dose of stable isotope-labeled phenobarbital, with plasma phenobarbital levels at a steady state. Plasma elimination of labeled phenobarbital was studied by selected ion monitoring. The addition of valproate to the phenobarbital regimen resulted in elevation of plasma phenobarbital and increase in urinary output of unchanged phenobarbital. There was no effect on urinary pH. The rise in plasma phenobarbital was paralleled by lengthening of phenobarbital elimination half-life while the decrease of plasma phenobarbital clearance paralleled the decrease in phenobarbital elimination rate constant. These findings suggest that inhibition of phenobarbital metabolism by valproate is the mechanism for this clinically important drug-drug interaction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6781810     DOI: 10.1038/clpt.1981.66

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  23 in total

Review 1.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 2.  Pharmacokinetic variability of phenobarbital: a systematic review of population pharmacokinetic analysis.

Authors:  Janthima Methaneethorn; Nattawut Leelakanok
Journal:  Eur J Clin Pharmacol       Date:  2020-10-19       Impact factor: 2.953

Review 3.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

Review 4.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

Review 5.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

Review 6.  Cytochrome P450-mediated estrogen catabolism therapeutic avenues in epilepsy.

Authors:  Megha Gautam; Ganesh Thapa
Journal:  Acta Neurol Belg       Date:  2020-08-02       Impact factor: 2.396

7.  Effect of the removal of individual antiepileptic drugs on antipyrine kinetics, in patients taking polytherapy.

Authors:  P N Patsalos; J S Duncan; S D Shorvon
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

8.  Inhibition of phenobarbitone N-glucosidation by valproate.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

Review 9.  Clinically relevant drug interactions with antiepileptic drugs.

Authors:  Emilio Perucca
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

10.  Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.

Authors:  G J Macphee; J R Mitchell; L Wiseman; A R McLellan; B K Park; G T McInnes; M J Brodie
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.